HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Acurx Pharmaceuticals (NASDAQ:ACXP) and maintained a $12 price target.
August 12, 2024 | 11:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Acurx Pharmaceuticals and maintained a $12 price target.
The reiteration of a Buy rating and maintenance of a $12 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100